OliX Pharmaceuticals (226950.KQ), an innovative drug developer based on RNA interference technology, said Wednesday that it will participate as an officially invited speaker at "TIDES USA 2026," a global RNA therapeutics conference to be held in Boston from May 11 to 14 local time.
At the conference, OliX CEO Lee Dong-ki has been invited as a speaker at a presentation session on May 14 local time, where he will introduce the company's eye disease treatment development strategy and research achievements based on its proprietary RNA interference (RNAi) platform "OASIS."
The presentation will unveil research results on an ophthalmic RNAi platform with enhanced delivery efficiency to retinal and retinal pigment epithelium (RPE) tissues, as well as a dual-target platform. The development status of "OLX301A," a macular degeneration treatment targeting MyD88, will also be introduced. OliX completed Phase 1 clinical trials of OLX301A in the United States last November and is currently preparing to enter Phase 2a trials for patients with dry macular degeneration.
TIDES USA is a leading conference in the RNA therapeutics field, bringing together global pharmaceutical companies, biotechs and CDMO firms, and serves as a venue to share the latest technologies and market trends across the industry, from R&D to manufacturing and commercialization strategies. The official presentation sessions, in particular, are composed mainly of major companies and research teams in RNA therapeutics and drug delivery technology, and are regarded as a key program for showcasing technological competitiveness and research achievements within the industry.
"This official speaker invitation is a meaningful case showing that OliX's RNAi platform technology and ophthalmic siRNA development capabilities are drawing attention in the global market," OliX CEO Lee Dong-ki said. "Through this presentation, we expect to showcase OliX's research competitiveness and next-generation ophthalmic RNAi platform technology on the international stage, and anticipate that it will serve as a positive catalyst for ongoing partnership discussions with global pharmaceutical companies."
Meanwhile, OliX is an innovative drug development company developing RNAi-based siRNA therapeutics that suppress specific gene expression. The company has been delivering visible results in the global market, including a 900 billion won ($660 million) technology transfer agreement signed with Eli Lilly last year.
